Clinical Trial Results Banner

AHA 2019

Dr. Daniel Judge Dr. Daniel Judge Presents: Long-term safety and efficacy of AG10 in ATTR-CM: Phase 2 Open Label Extension - Sponsored by an unrestricted educational grant from Eidos Therapeutics Slides

Dr. Daniel Judge Presents: ATTRibute-CM: A randomized, double-blind, placebo-controlled, multi-center, global Phase 3 study of AG10 in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) - Sponsored by an unrestricted educational grant from Eidos Therapeutics Poster


Dr. Uma Sinha Dr. Uma Sinha Presents: Differential Ex Vivo Stabilization Of Transthyretin By AG10 And Tafamidis In Samples From Patients With Moderately Or Severely Destabilizing Mutations - Sponsored by an unrestricted educational grant from Eidos Therapeutics Poster

Dr. Uma Sinha Presents: Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis - Sponsored by an unrestricted educational grant from Eidos Therapeutics Poster

Who Are We? Slide Downloading Policy Financial Disclosure We Do Not Promote Off Label Product Use Copyright Editorial Policy Links Policy Privacy Policy Access CME Programs

Last Edited and Updated 11/18/2019 03:53:26 PM -0500